Krishna Institute Of Medical Sciences Ltd moves to reshape its capital structure

Issue price: Rs 779 per warrant.

Expected total capital infusion on full conversion: Rs 5,999,999,778, or approximately Rs 600 Crores.

Derivation: The filing records 77,02,182 warrants and upfront receipt of Rs 1,499,999,944.50, representing 25% of the issue price. Therefore:

• Total issue consideration = Rs 1,499,999,944.50 ÷ 25% = Rs 5,999,999,778
• Issue price per warrant = Rs 5,999,999,778 ÷ 77,02,182 = Rs 779
• Additional 75% payable on conversion = approximately Rs 450 Crores, with the upfront 25% already received. ^[1]

The Rs 600 Crores represents the total consideration, not merely the balance payable at conversion; the warrants are convertible into equity shares within 18 months, with the remaining 75% payable upon conversion. ^[1]

The preferential-allotment filing does not earmark the proceeds to a specific use such as debt repayment, hospital construction, acquisitions, or general corporate purposes. It records the allotment of 77,02,182 warrants and receipt of 25% of the issue consideration—Rs 150.00 Crores—while the remaining Rs 450.00 Crores is payable when the warrants are converted into equity shares within 18 months. ^{[2] [1]}

Fit with leverage

KIMS entered this fund raise with a relatively leveraged consolidated balance sheet:

• Q4 FY26 debt-to-equity was 1.44x and net debt-to-equity was 1.42x. ^{[3] [4]}
• Consolidated net debt was Rs 3,188.6 Crores, against total equity of Rs 2,247.4 Crores. ^{[5] [6]}
• TTM net debt/EBITDA was 3.85x, while TTM interest coverage had declined to 2.64x, indicating that incremental non-debt funding is strategically useful as expansion continues. ^{[7] [8]}

The immediate Rs 150.00 Crores represents approximately 4.70% of current consolidated net debt, while the full Rs 600.00 Crores warrant consideration would represent approximately 18.82%, derived from the disclosed proceeds and net debt. This would provide meaningful balance-sheet support if used for debt reduction, but the filing does not say that it will be.

Fit with bed-addition capex

Earlier Nuvama coverage described an approximately Rs 1,200 Crores capex programme to add around 1,880 beds by Q1 FY27, with funding expected mainly through internal accruals and minimal debt dependence. ^[9] Separately, coverage refers to 2,500-plus planned new beds across Bengaluru, Thane, Andhra Pradesh and Telangana, but does not quantify the associated capex. ^[10]

Against the older Rs 1,200 Crores capex reference:

• The upfront Rs 150.00 Crores equals approximately 12.50% of that amount.
• The full Rs 600.00 Crores warrant consideration equals approximately 50.00%.

These are scale comparisons, not disclosed allocations. The capital raise is therefore consistent with funding part of the expansion while limiting further borrowing, but the stated documents do not establish whether the proceeds will fund new beds, refinance debt, or another corporate purpose. Moreover, the funding is only partly received today: the remaining 75% is conditional on warrant conversion, and paid-up equity had not yet changed at allotment. ^[11]

KIMS’s maximum dilution from this warrant issue is approximately 1.79% for existing public shareholders on a relative basis. Their aggregate ownership would decline from 67.50% to 66.29%, equivalent to a 1.21 percentage-point reduction in the company’s equity ownership, assuming all 77,02,182 warrants are converted 1:1 within 18 months. ^{[1] [1] [1]}

KIMS dilution mechanics

• The warrants do not immediately dilute paid-up equity capital at allotment; dilution occurs only if exercised. ^[11]
• Public ownership after conversion: 100% − 33.71% promoter/promoter-group ownership = 66.29%. ^[1]
• Relative dilution to existing public holders: `(67.50% − 66.29%) / 67.50%` = approximately 1.79%, derived from the reported pre- and post-conversion ownership figures. ^[1]
• The transaction is a staged promoter infusion: KIMS received approximately Rs 150 Crores upfront, while approximately Rs 450 Crores remains payable on conversion, implying total potential proceeds of approximately Rs 600 Crores. ^{[1] [2]}

This is therefore a targeted, promoter-led and relatively modest dilution event, rather than an immediate broad-based equity issue. The trade-off is that promoter concentration rises by 1.21 pp, while the company receives the remaining capital only if the warrants are exercised.

Comparison with named hospital peers

• Narayana Health: The recent disclosed capital-allocation item concerns planned Rs 3,000 Crores of expansion capex, not a quantified equity issue with pre- and post-raise share counts. ^[12]
• Medanta: The cited transaction is an acquisition of an 80-bed cancer hospital for Rs 30 Crores, rather than a disclosed primary equity raise. ^[13]
• Aster DM Healthcare: Recent coverage focuses on the Aster–Quality Care merger and planned Rs 1,661 Crores of investment, but does not provide comparable share-issuance or ownership-dilution terms. ^[14]
• Dr Agarwal’s Eye Hospital: The cited item relates to IPO details, without sufficient post-listing capital-raise terms to calculate a comparable dilution percentage. ^[15]
• Rainbow Children’s Medicare: The recent cited item is an operating update; its reference to “EBITDA dilution” is an earnings-impact concept, not equity-share dilution. ^[16]

Analyst read: KIMS’s transaction is clearly more concentrated than a QIP or IPO because only promoters and a promoter-group entity receive the warrants, but the measured public-shareholder dilution is only about 1.79% relative to their existing holding. A precise ranking against peers is not supportable because the cited peer disclosures do not provide the corresponding issue sizes and pre/post share counts; the available evidence points to capex, acquisitions, mergers and IPO-related events rather than a uniform pattern of recent follow-on equity dilution.